Trade ANI Pharma - ANIP CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.39
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.022262 %(-$4.45)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02226%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00004 %($0.01)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: 0.00004%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.022262 %
  (-$4.45)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00004 %
  ($0.01)

Key Stats

• Prev. Close: 73.88
• Open: 72.95
• 1-Year Change: -21.54%
• Day's Range: 72.94 - 74.68

Trade ANI Pharma - ANIP

About ANI Pharmaceuticals Inc

ANI Pharmaceuticals, Inc. is an integrated specialty pharmaceutical company. The Company is focused on developing, manufacturing, and marketing branded and generic prescription pharmaceuticals. The Company focuses on areas, including controlled substances, oncology products (anti-cancer), hormones and steroids, and complex formulations. The Company’s products include both branded and generic pharmaceuticals. Its generic products include Aspirin and Extended Release Dipyridamole, Bretylium Tosylate Injection USP, cholestyramine, Etodolac, Fluvoxamine, Indapamide, Nilutamide, Vancomycin and more. Its branded products include Arimidex (anastrozole) tablets, Atacand HCT Tablets, Atacand (candesartan cilexetil) Tablets, Casodex, Cortenema, Cortrophin gel, Cortrophin-Zinc, Inderal LA, Inderal XL, InnoPran XL, Lithobid, Reglan and Vancocin. It operates across three pharmaceutical manufacturing facilities, of which two are located in Baudette, Minnesota and one is located in Oakville, Ontario.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, ANI Pharmaceuticals Inc revenues increased 4% to $216.1M. Net loss applicable to common stockholders increased 90% to $42.8M. Revenues reflect Royalties from licensing agreements segment increase from $1.4M to $11.8M, Other segment increase from $783K to $1.9M, United States segment increase of 4% to $211.9M. Higher net loss reflects Selling.

Equity composition

6Common Stock $.0001 Par, 3/10, unlim. auth., 93,590,612 issd. Insiders own 2.43%. IPO: N/A. Cl. C Common no Par, 12/10, unlim. auth., 391,286 issd. 5/31/02 1-for-10 reverse stock split. *7/06, private placement of 3,812,978 shares @ 04/06, 1-for-6 Reverese stock split. 07/13, 1-for-6 Reverese stock split.